Aldesleukin: all 184 studies that test it

Page 1 of 2. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.

• Study Evaluating a Gene Therapy for IPEX Syndrome Through the Expression of FOXP3 on Deficient T Cells to Produce Tregs-like.Not yet recruitingNCT07697118Phase 1/2
• A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic MelanomaNot yet recruitingNCT07651618Phase 2
• Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal TumorsNot yet recruitingNCT07647068Phase 2
• Use of Low Doses of Interleukin-2 in Autism Spectrum DisordersNot yet recruitingNCT07589842Phase 2
• Adding IL-2 to Tebentafusp to Eradicate Cancer ProgressionRecruitingNCT07063875Phase 1/2
• Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingNCT06904066Phase 1
• Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological TumorsRecruitingNCT06584006Phase 2
• IL-2 Plus Abatacept in FTDRecruitingNCT06395038Phase 1
• Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung CancerRecruitingNCT05493566Early Phase 1
• Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersRecruitingNCT05296564Phase 1/2
• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell CarcinomaRecruitingNCT05155033Phase 2
• Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 DiabetesRecruitingNCT05153070Phase 2
• Low Dose IL-2 for the Treatment of Crohn's DiseaseRecruitingNCT04263831Phase 1/2
• Immunotherapy for the Treatment of Advanced Solid TumorRecruitingNCT03658785Phase 1/2
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersRecruitingNCT02830724Phase 1/2
• T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerRecruitingNCT02133196Phase 2
• High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)RecruitingNCT01704716Phase 3
• Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsTerminatedNCT05194735Phase 1/2Results posted
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 PatientsTerminatedNCT03745326Phase 1/2Results posted
• T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian CancerCompletedNCT03318900Phase 1/2Results posted
• Adoptive Cell Therapy Across Cancer DiagnosesCompletedNCT03296137Phase 1/2Results posted
• Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney CancerTerminatedNCT03260504Phase 1Results posted
• Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2TerminatedNCT03233828Phase 3Results posted
• Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host DiseaseCompletedNCT03007238Phase 2Results posted
• Anti-NY ESO-1 mTCR Peripheral Blood LymphocytesTerminatedNCT02774291Early Phase 1Results posted
• Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid LeukemiaTerminatedNCT02770820Phase 1/2Results posted
• Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV MelanomaTerminatedNCT02748564Phase 2Results posted
• BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic CancerCompletedNCT02620865Phase 1/2Results posted
• Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic MelanomaCompletedNCT02500576Phase 2Results posted
• Ultra-low Dose Subcutaneous IL-2 in Renal TransplantationTerminatedNCT02417870Phase 1/2Results posted
• T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated CancersCompletedNCT02280811Phase 1/2Results posted
• High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By SurgeryTerminatedNCT02203604Phase 2Results posted
• Low Dose IL-2 for Ulcerative ColitisCompletedNCT02200445Phase 1Results posted
• T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 PositiveTerminatedNCT02153905Phase 1/2Results posted
• T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 PositiveCompletedNCT02111850Phase 1/2Results posted
• T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing MelanomaTerminatedNCT02062359Phase 2Results posted
• CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic MelanomaCompletedNCT02027935Phase 2Results posted
• Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesCompletedNCT01823198Phase 1/2Results posted
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular MelanomaTerminatedNCT01814046Phase 2Results posted
• Combined BRAF-Targeted Therapy & Immunotherapy for MelanomaTerminatedNCT01754376Phase 2Results posted
• Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic MelanomaCompletedNCT01740557Phase 1/2Results posted
• ch14.18 Pharmacokinetic Study in High-risk NeuroblastomaCompletedNCT01592045Phase 1/2Results posted
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated CancersCompletedNCT01585428Phase 2Results posted
• Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor CellsTerminatedNCT01495572Phase 2Results posted
• Drosophila-generated CTLTerminatedNCT01271907Phase 2Results posted
• Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal CancerTerminatedNCT01160445Phase 2Results posted
• Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedNCT01041638Phase 3Results posted
• Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney CancerActive, not recruitingNCT01038778Phase 1/2Results posted
• Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic CancerTerminatedNCT00924287Phase 1/2Results posted
• Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AMLTerminatedNCT00871689Phase 2Results posted
• Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the KidneyCompletedNCT00853021Phase 2Results posted
• Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast CaTerminatedNCT00784524Phase 2Results posted
• Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic CancerTerminatedNCT00704938Phase 2Results posted
• Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat MelanomaCompletedNCT00665470Phase 2Results posted
• Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT00625729Phase 1/2Results posted
• The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell CarcinomaCompletedNCT00554515Phase 2Results posted
• Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic MelanomaCompletedNCT00414765Phase 4Results posted
• Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.TerminatedNCT00354172Phase 2Results posted
• Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell TransplantCompletedNCT00303667Phase 1/2Results posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00274846Phase 2Results posted
• Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00126490Phase 2Results posted
• Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00096382Phase 2Results posted
• DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCCCompletedNCT00085436Phase 2Results posted
• Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic MelanomaCompletedNCT00085423Phase 2Results posted
• Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With NeuroblastomaCompletedNCT00026312Phase 3Results posted
• Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)CompletedNCT00013611Phase 3Results posted
• Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple MyelomaCompletedNCT00006244Phase 2Results posted
• Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00003875Phase 2Results posted
• Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast CancerCompletedNCT00003199Phase 2Results posted
• A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal MalignanciesWithdrawnNCT06690281Phase 2
• STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and MelanomaWithdrawnNCT06626256Phase 1
• Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerActive, not recruitingNCT06253520Phase 1
• Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma PatientsCompletedNCT06152367Phase 1/2
• Low Dose IL2 Immunotherapy in ADCompletedNCT05821153Phase 1
• Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal MetastasisActive, not recruitingNCT05802056Phase 1
• Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early ADActive, not recruitingNCT05468073Phase 2
• Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous UrticariaStatus unknownNCT04893980Phase 2/3
• TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid TumorCompletedNCT04862767Phase 1
• Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)CompletedNCT04724629Phase 3
• A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma PatientsStatus unknownNCT04383067Phase 2
• Low Dose IL-2 Therapy in Patients With a Depressive Episode in the Course of a Bipolar DisorderCompletedNCT04133233Phase 2
• Non-Viral TCR Gene TherapyWithdrawnNCT04102436Phase 2
• Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus VulgarisStatus unknownNCT04023149Phase 2
• Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy VolunteersCompletedNCT03837093Phase 1
• Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)Active, not recruitingNCT03782636Phase 2
• Safety and Efficacy of Low-dose IL-2 in Birch Pollen AllergyCompletedNCT03776643Phase 2
• Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedNCT03691376Phase 1
• TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple MyelomaWithdrawnNCT03506802Phase 1
• Low-dose Interleukin-2 for Treatment of Systemic Lupus ErythematosusCompletedNCT03312335Phase 2
• Low-dose IL-2 in Established T1D - The "PROREG" StudyWithdrawnNCT03243058Phase 1/2
• Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced CancerTerminatedNCT03240861Phase 1
• Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary SyndromesCompletedNCT03113773Phase 1/2
• Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaActive, not recruitingNCT03068624Phase 1
• ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)CompletedNCT02955615Phase 2
• IL-2 in Refractory Autoimmune EncephalitisCompletedNCT02714959Phase 1/2
• Autologous Stem Cell Transplant for Refractory Crohn's DiseaseWithdrawnNCT02676622Phase 2
• T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive SystemStatus unknownNCT02662348Phase 1
• NB2013-HR German (GPOH) / Dutch (DCOG) TrialTerminatedNCT02641782Phase 2
• In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic MelanomaWithdrawnNCT02489266Phase 1
• Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or RecurrentWithdrawnNCT02470559Phase 1

← Aldesleukin overview